Amp Volatility Score
Catalyst Info & Data Links
TITLE: Uproleselan/GMI-1687 for Relapsed/Refractory AML - Phase 3
ClinicalTrial.gov (NCT03616470): Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia
WHAT IS THE NEXT CATALYST EVENT?
Completion of Enrollment
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
MECHANISM OF ACTION
Discovered and developed by GlycoMimetics, uproleselan is an investigational, first-in-class, targeted inhibitor of E-selectin.
Updated by JM
GLYC, Glycomimetics, Uproleselan/GMI-1687, Relapsed/Refractory AML
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See What The Community Is Saying - Click To See Full Post